8-K: Corcept Reports Q3 Growth, Oncology Pipeline Expansion

Corcept Therapeutics announced third-quarter 2025 financial results with revenue growth and expanded oncology development programs, alongside modified full-year guidance.

Summary

• Third quarter 2025 revenue was $207.6 million, an increase from $182.5 million in the third quarter of 2024.
• Modified 2025 revenue guidance is set at $800 million to $850 million.
• Net income for Q3 2025 was $19.7 million, a decrease from $47.2 million in Q3 2024.
• Cash and investments stood at $524.2 million as of September 30, 2025, up from $515.0 million at June 30, 2025.
• Operating expenses increased to $197.4 million in Q3 2025 from $135.9 million in Q3 2024, primarily due to preparations for relacorilant launches.
• Diluted net income per common share was $0.16 in Q3 2025, compared to $0.41 in Q3 2024.
• The New Drug Application (NDA) for relacorilant in hypercortisolism has a PDUFA date of December 30, 2025.
• The NDA for relacorilant in platinum-resistant ovarian cancer has a PDUFA date of July 11, 2026.
• Oncology development programs expanded to include new studies in earlier-stage ovarian, endometrial, cervical, and pancreatic cancers, as well as broad range of solid tumors in combination with immunotherapy.
• The company acquired $50.6 million of common stock in the third quarter through its stock repurchase program.

Sentiment

Score: 6

Explanation: While revenue growth for Korlym is robust and the clinical pipeline shows significant progress with multiple upcoming milestones and positive trial data (relacorilant in PROC, dazucorilant in ALS), the substantial decrease in net income and EPS, coupled with increased operating expenses and acknowledged capacity constraints impacting revenue, creates a mixed financial picture. The long-term potential from the pipeline is strong, but current profitability is a concern.

Positives

• Record number of new prescriptions written for Korlym and continued growth in the prescriber base.
• Third quarter 2025 revenue increased to $207.6 million from $182.5 million in Q3 2024, demonstrating robust growth in the hypercortisolism business.
• Cash and investments increased to $524.2 million at September 30, 2025, from $515.0 million at June 30, 2025.
• Relacorilant NDA for hypercortisolism has a PDUFA date of December 30, 2025, indicating potential near-term approval.
• Relacorilant NDA for platinum-resistant ovarian cancer has a PDUFA date of July 11, 2026, with European MAA approval expected by end of next year.
• The pivotal Phase 3 ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its primary endpoint, showing improved progression-free and overall survival without increased safety burden.
• Expanded oncology pipeline with new Phase 2 trials for relacorilant in earlier-stage ovarian, endometrial, cervical, and pancreatic cancers, and a Phase 1b trial for nenocorilant in solid tumors.
• DAZALS trial for dazucorilant in ALS showed an 84% reduction in risk of death during the first year compared to placebo (hazard ratio: 0.16, p-value: 0.0009).
• Miricorilant in Phase 1b MASH study was well-tolerated and rapidly reduced liver fat, improving liver enzymes and other health markers.
• New specialty pharmacy added on October 1st, with plans for more, to address capacity constraints and meet increasing demand for Korlym.

Negatives

• Net income significantly decreased to $19.7 million in Q3 2025 from $47.2 million in Q3 2024.
• Diluted net income per common share decreased to $0.16 in Q3 2025 from $0.41 in Q3 2024.
• Operating expenses increased substantially to $197.4 million in Q3 2025 from $135.9 million in Q3 2024, impacting profitability.
• Financial results did not fully reflect the surge in demand for Korlym due to capacity constraints at the previous specialty pharmacy vendor.

Risks

• Ability to operate the business effectively.
• Challenges in studying and developing Korlym, relacorilant, miricorilant, dazucorilant, nenocorilant, and other product candidates.
• Uncertainties related to the clinical attributes, regulatory approvals, mandates, oversight, and other requirements for the company's molecules.
• Risks concerning the scope and protective power of the company's intellectual property.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties outlined in SEC filings.

Future Outlook

Corcept anticipates meeting the PDUFA deadlines for relacorilant in hypercortisolism (December 30, 2025) and platinum-resistant ovarian cancer (July 11, 2026). Key clinical trial results are expected by early next year for MOMENTUM and ROSELLA (final overall survival), and by the end of next year for BELLA and MONARCH. The company plans to initiate new Phase 2 and Phase 1b trials for various cancers and a Phase 3 trial for ALS in the coming weeks to mid-next year. Management is confident that the addition of new specialty pharmacies will enable the company to meet the increasing demand for Korlym.

Management Comments

• Joseph K. Belanoff, M.D., CEO: "The third quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a record number of new prescriptions written for Korlym and continued to add to our base of prescribers. Growing recognition among physicians of hypercortisolisms true prevalence and the necessity of appropriate treatment is driving higher rates of screening and diagnosis. Our financial results dont fully reflect this surge in demand, given capacity constraints at our previous specialty pharmacy vendor. We have modified our 2025 revenue guidance to $800 $850 million. We added a new specialty pharmacy on October 1st and will add others in the coming months. We are confident that these additions will allow us to meet the increasing demand that we now see every month."
• Joseph K. Belanoff, M.D., CEO: "We are approaching important clinical development milestones... We believe both deadlines will be met."
• Bill Guyer, PharmD, Chief Development Officer: "Relacorilant has the potential to become the new standard of care for patients with hypercortisolism. In its Phase 2 and Phase 3 studies, patients treated with relacorilant showed clinically meaningful and statistically significantly improvements in a wide range of hypercortisolisms signs and symptoms, without off-target effects and toxicities associated with currently available treatments."
• Bill Guyer, PharmD, Chief Development Officer: "We are seeking approval of relacorilant in patients with platinum-resistant ovarian cancer (PROC) in both the United States and Europe based on positive data from our Phase 2 and pivotal Phase 3 ROSELLA trials. These trials groundbreaking results, in which relacorilant improved progression-free and overall survival in patients with a highly challenging form of ovarian cancer without increasing the safety burden of the patients who took it, highlight relacorilants potential to become the new standard care in PROC."
• Bill Guyer, PharmD, Chief Development Officer: "ALS is a devastating disease linked to elevated cortisol activity. In our DAZALS study, patients who received dazucorilant experienced a profound reduction in early mortality a time during which many patients with ALS retain significant function and quality of life. We aim to replicate these findings in a Phase 3 trial and are working with regulatory authorities and leading ALS clinicians to finalize our study design."

Industry Context

Corcept Therapeutics' focus on cortisol modulation positions it uniquely in the endocrinology and oncology sectors. The expansion of its oncology pipeline into various solid tumors and combination therapies aligns with broader industry trends towards targeted and multi-modal cancer treatments. The emphasis on identifying the true prevalence of hypercortisolism through studies like MOMENTUM and CATALYST addresses an underdiagnosed condition, potentially expanding the market for cortisol modulators. Furthermore, the development of treatments for MASH and ALS targets areas with high unmet medical needs, reflecting a strategic move into diverse therapeutic areas.

Comparison to Industry Standards

• The ROSELLA trial results for relacorilant in platinum-resistant ovarian cancer are described as "groundbreaking" and suggest its potential to become the "new standard care in PROC," implying superior efficacy and safety compared to existing limited treatment options for this challenging patient population.
• The DAZALS trial for dazucorilant in ALS demonstrated an "84 percent reduction in risk of death during the studys first year compared to patients who received placebo," which is a highly significant outcome in a disease with very few effective treatments, potentially setting a new benchmark for early mortality reduction.
• Corcept's proprietary selective cortisol modulators and glucocorticoid receptor antagonists offer a distinct mechanism of action compared to many conventional therapies, potentially providing advantages in terms of efficacy and side effect profiles in various severe disorders.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline advancements and market expansion for Korlym, but short-term profitability concerns due to increased expenses and lower net income. The stock repurchase program ($50.6 million in Q3) indicates management's confidence and returns capital.
• Patients: Potential for new and improved treatments for hypercortisolism, platinum-resistant ovarian cancer, ALS, MASH, and other solid tumors.
• Physicians: Increased recognition of hypercortisolism prevalence and new treatment options for various severe disorders.
• Employees: Continued investment in R&D and launch preparations suggests stable to growing employment opportunities.
• Suppliers/Vendors: Increased operating expenses and R&D spending indicate continued business for suppliers. New specialty pharmacy additions will impact vendor relationships.

Next Steps

• Add additional specialty pharmacies in the coming months to meet increasing demand for Korlym.
• FDA review of relacorilant NDA for hypercortisolism, with a PDUFA date of December 30, 2025.
• FDA review of relacorilant NDA for platinum-resistant ovarian cancer, with a PDUFA date of July 11, 2026.
• European Medicines Agency review of MAA for relacorilant in platinum-resistant ovarian cancer, with approval expected by the end of next year.
• Expect results from the MOMENTUM trial by early next year.
• Expect final overall survival results from the ROSELLA trial by early next year.
• Expect results from the BELLA trial in advanced ovarian cancer by the end of next year.
• Expect results from the MONARCH Phase 2b trial in MASH by the end of next year.
• Initiate a Phase 3 trial of dazucorilant in ALS by the middle of next year.
• Initiate Phase 2 trials of relacorilant in combination with chemotherapy for earlier-stage ovarian, endometrial, cervical, and pancreatic cancers in the coming weeks.
• Initiate a Phase 1b trial of nenocorilant in combination with immunotherapy in patients with a broad range of solid tumors in the coming weeks.
• Continue enrollment in the Phase 2 trial of relacorilant plus enzalutamide in prostate cancer.

Key Dates

Recommendation

While Corcept demonstrates strong revenue growth for its existing product Korlym and has a robust clinical pipeline with several promising candidates nearing key milestones and positive trial data (relacorilant in PROC, dazucorilant in ALS), the significant decline in net income and EPS due to increased operating expenses is a concern. The modified revenue guidance, influenced by past capacity constraints, suggests potential for higher revenue if not for these issues. The long-term growth potential from new drug approvals and pipeline expansion is substantial, but the current financial performance indicates a period of heavy investment impacting profitability. Investors should hold to monitor the successful execution of pipeline milestones and the impact of new pharmacy partnerships on future revenue and profitability.

Keywords

Corcept Therapeutics, CORT, Hypercortisolism, Cushing's Syndrome, Korlym, Relacorilant, Oncology, Ovarian Cancer, Platinum-Resistant Ovarian Cancer, ALS, Dazucorilant, MASH, Miricorilant, Nenocorilant, Glucocorticoid Receptor Antagonist, Pharmaceutical, Biotechnology, Clinical Trials, FDA, PDUFA, NDA, MAA, Revenue, Net Income, Drug Development